melanoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Altogether, 36 samples were classified into RAS/BRAF/NF1 mutant (n = 14, 39%) or triple wild-type (n = 22, 61%) melanoma subtypes.
|
31826932 |
2020 |
melanoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAF V600E/K mutant melanoma.
|
31796433 |
2020 |
melanoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Targeted BRAF and MEK inhibition has become an appropriate first-line treatment of BRAF-mutant advanced cutaneous melanoma.
|
31753111 |
2020 |
melanoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Neoadjuvant BRAF-targeted therapy is associated with a high pCR rate in patients with stage III-IV melanoma, which may correlate with improved RFS and OS.
|
31329344 |
2020 |
melanoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
However, the molecular rationale for this treatment combination was based on the presence of the BRAF mutation and the efficacy observed in other cancer types such as melanoma.
|
31672771 |
2020 |
melanoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
In this review, we will focus on the current clinical development of targeted therapies beyond BRAF, in NRAS-mutated and KIT-altered melanoma.
|
31833955 |
2020 |
melanoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We quantified cfBRAF<sup>V</sup><sup>600E</sup> by droplet digital polymerase chain reaction in plasma from 146 patients without melanoma undergoing continuous dermatological screening, from 26 stage III and seven stage IV patients with BRAF-mutant melanoma, and from 32 patients with melanoma who were free of disease for 3 or more years.
|
31102256 |
2020 |
melanoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Mutation of the oncogene BRAF is among the most common genetic alterations in melanoma.
|
31744894 |
2020 |
melanoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Melanoma is a deadly tumor which in recent years has been successfully treated with immune checkpoint inhibitors as PD-1/PD-L1 and CTLA-4 inhibitors and targeted therapy as BRAF and MEK inhibitors.
|
31785018 |
2020 |
melanoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Since melanoma acquired resistance to BRAF inhibitors (BRAFi) has been associated with activation of pro-angiogenic pathways, we have investigated VEGFR-1 involvement in vemurafenib resistance.
|
31758648 |
2020 |
melanoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Populations in Brazil, the US, Sweden, Italian, and Australia were found to be correlated to mutations of BRAF and melanoma.
|
31274706 |
2020 |
melanoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
From Breslow to BRAF and immunotherapy: evolving concepts in melanoma pathogenesis and disease progression and their implications for changing management over the last 50years.
|
31704364 |
2020 |
melanoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
This study revealed an interesting finding that MMP-1 and MMP-13 protein expression in the BRAF V600 mutated melanomas were significantly lower than in the BRAF V600 wild type (P < 0.05).
|
31677173 |
2020 |
melanoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Somatic oncogenic mutation of BRAF coupled with inactivation of PTEN constitute a frequent combination of genomic alterations driving the development of human melanoma.
|
31065107 |
2020 |
melanoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Altogether, our data highlight heterogeneity in metabolic adaptations during acquired resistance to vemurafenib in BRAF-mutant melanoma, potentially uncovering key clinically-relevant mechanisms for combinatorial therapeutic targeting.
|
31819183 |
2020 |
melanoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
The clinical characteristics of melanoma with BRAF V600R mutation: a case series study.
|
31305324 |
2020 |
melanoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma.
|
31839677 |
2020 |
melanoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Here we review current knowledge on how oncogenic signaling reprograms metabolism in BRAF-mutated melanoma, and discuss how NAMPT/NAD<sup>+</sup> axis contributes to these processes.
|
31059816 |
2020 |
melanoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Small molecules tackling mutated BRAF (BRAFi) are an important mainstay of targeted therapy in a variety of cancers including melanoma.
|
31618797 |
2020 |
melanoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
While under normoxic conditions the expression of glycolysis-related genes showed no correlation with origin or BRAF mutation status, GLUT1 expression was significantly elevated in metastatic and BRAF-V600E mutated melanoma cell lines under hypoxic conditions.
|
31791701 |
2020 |
melanoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
The case was observed in a young patient with BRAF mutant melanoma who was started on first-line metastatic immunotherapy with pembrolisumab.
|
31750971 |
2020 |
melanoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Confirmed partial responses were observed in patients with BRAF-mutant melanoma (n = 1) and KRAS-mutant endometrioid adenocarcinoma (n = 1).
|
31020608 |
2020 |
melanoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
LY3009120, a pan-RAF and dimer inhibitor, has preclinical activity in RAS- and BRAF-mutated cell lines including BRAF-mutant melanoma resistant to BRAF inhibitors.
|
31645440 |
2020 |
melanoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Therapeutic success of targeted therapy with BRAF inhibitors (BRAFi) for melanoma is limited by resistance development.
|
31702822 |
2020 |
melanoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
We now show that the majority of BRAF/RAS WT melanoma cell lines (8/13) display some degree of sensitivity to trametinib treatment and resistance to trametinib in this melanoma subtype is associated with, but not mediated by NF1 suppression.
|
31518489 |
2020 |